Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ENANTA PHARMACEUTICALS INC (ENTA)
|
Add to portfolio |
|
|
|
| Price: |
$74.11
| | Metrics |
| OS: |
21.1
|
M
| |
|
|
| Market cap: |
$1.56
|
B
| |
-46
|
% ROIC
|
|
Net cash:
|
$393
|
M
| |
$18.64
|
per share
|
|
EV:
|
$1.17
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($145)
|
M
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-05-21 | Sep-30-20 | Sep-05-20 | Sep-30-19 | Sep-30-18 | Sep-30-17 |
| Revenues | 86.2 | 97.1 | 97.1 | 122.5 | 122.5 | 205.2 | 206.6 | 102.8 |
| Revenue growth | -11.2% | -20.7% | -20.7% | -40.3% | | -0.7% | 101.0% | 16.5% |
| Cost of goods sold | 210.0 | 206.6 | 206.6 | 164.1 | 164.1 | 168.5 | 0.0 | 0.0 |
| Gross profit | -123.8 | -109.6 | -109.6 | -41.6 | -41.6 | 36.7 | 206.6 | 102.8 |
| Gross margin | -143.7% | -112.9% | -112.9% | -34.0% | -34.0% | 17.9% | 100.0% | 100.0% |
| Selling, general and administrative | 0.0 | 0.0 | | 0.0 | | 0.0 | | |
| Research and development | | | | | | | 94.9 | 57.5 |
| General and administrative | 0.0 | 0.0 | 32.5 | 0.0 | 27.4 | 0.0 | 23.4 | 20.7 |
| EBIT | -122.2 | -107.7 | -109.6 | -35.1 | -41.6 | 45.6 | 88.3 | 24.6 |
| EBIT margin | -141.8% | -110.9% | -112.9% | -28.6% | -34.0% | 22.2% | 42.7% | 23.9% |
| Pre-tax income | -122.2 | -107.6 | -107.6 | -35.0 | -35.0 | 45.6 | 93.1 | 26.9 |
| Income taxes | -0.4 | -28.6 | -28.6 | 1.1 | 1.1 | -0.8 | 21.2 | 9.2 |
| Tax rate | 0.4% | 26.6% | 26.6% | | | | 22.7% | 34.3% |
| Net income | -121.8 | -79.0 | -79.0 | -36.2 | -36.2 | 46.4 | 72.0 | 17.7 |
| Net margin | -141.3% | -81.4% | -81.4% | -29.5% | -29.5% | 22.6% | 34.8% | 17.2% |
| |
| Diluted EPS | ($5.91) | ($3.92) | ($3.92) | ($1.81) | ($1.81) | $2.21 | $3.48 | $0.91 |
| Shares outstanding (diluted) | 20.6 | 20.2 | 20.2 | 19.9 | 19.9 | 21.0 | 20.7 | 19.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|